The Food and Drug Administration authorized extra doses of a COVID-19 vaccine for people with fragile immune systems who were not sufficiently protected after the first vaccination regimen.
“After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines,” FDA Commissioner Janet Woodcock said.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.